It’s surprisingly hard to tell when a brain cell is dead. Neurons that appear inactive and fragmented under the microscope can persist in a kind of life-or-death limbo for days, and some suddenly begin signaling again after appearing inert. For researchers who study neurodegeneration, this lack of a precise “time of death” declaration for neurons makes it hard to pin down what factors lead to cell death and to screen drugs that might save aging cells from dying.
Now, researchers at Gladstone Institutes have developed a new technology that lets them track thousands of cells at a time and determine the precise moment of death for any cell in the group. The team showed, in a paper published in the journal Nature Communications, that the approach works in rodent and human cells as well as within live zebrafish, and can be used to follow the cells over a period of weeks to months.
“Getting a precise time of death is very important for unraveling cause and effect in neurodegenerative diseases,” says Steve Finkbeiner, MD, PhD, director of the Center for Systems and Therapeutics at Gladstone and senior author of both new studies. “It lets us figure out which factors are directly causing cell death, which are incidental, and which might be coping mechanisms that delay death.”
In a companion paper published in the journal Science Advances, the researchers combined the cell sensor technology with a machine learning approach, teaching a computer how to distinguish live and dead cells 100 times faster and more accurately than a human.
“It took college students months to analyze these kind of data by hand, and our new system is nearly instantaneous—it actually runs faster than we can acquire new images on the microscope,” says Jeremy Linsley, PhD, a scientific program leader in Finkbeiner’s lab and the first author of both new papers.
When cells die—whatever the cause or mechanism—they eventually become fragmented and their membranes degenerate. But this degradation process takes time, making it difficult for scientists to distinguish between cells that have long since stopped functioning, those that are sick and dying, and those that are healthy.
Researchers typically use fluorescent tags or dyes to follow diseased cells with a microscope over time and try to diagnose where they are within this degradation process. Many indicator dyes, stains, and labels have been developed to distinguish the already dead cells from those that are still alive, but they often only work over short periods of time before fading and can also be toxic to the cells when they are applied.
“We really wanted an indicator that lasts for a cell’s whole lifetime—not just a few hours—and then gives a clear signal only after the specific moment the cell dies,” says Linsley.
Linsley, Finkbeiner, and their colleagues co-opted calcium sensors, originally designed to track levels of calcium inside a cell. As a cell dies and its membranes become leaky, one side effect is that calcium rushes into the cell’s watery cytosol, which normally has relatively low levels of calcium.
So, Linsley engineered the calcium sensors to reside in the cytosol, where they would fluoresce only when calcium levels increased to a level that indicates cell death. The new sensors, known as genetically encoded death indicator (GEDI, pronounced like Jedi in Star Wars), could be inserted into any type of cell and signal that the cell is alive or dead over the cell’s entire lifetime.
To test the utility of the redesigned sensors, the group placed large groups of neurons—each containing GEDI—under the microscope. After visualizing more than a million cells, in some cases prone to neurodegeneration and in others exposed to toxic compounds, the researchers found that the GEDI sensor was far more accurate than other cell death indicators: there wasn’t a single case where the sensor was activated and a cell remained alive. Moreover, in addition to that accuracy, GEDI also seemed to detect cell death at an earlier stage than previous methods—close to the “point of no return” for cell death.
“This allows you to separate live and dead cells in a way that’s never been possible before,” says Linsley.
Linsley mentioned GEDI to his brother—Drew Linsley, PhD, an assistant professor at Brown University who specializes in applying artificial intelligence to large-scale biological data. His brother suggested that the researchers use the sensor, coupled with a machine learning approach, to teach a computer system to recognize live and dead brain cells based only on the form of the cell.
The team coupled results from the new sensor with standard fluorescence data on the same neurons, and they taught a computer model, called BO-CNN, to recognize the typical fluorescence patterns associated with what dying cells look like. The model, the Linsley brothers showed, was 96 percent accurate and better than what human observers can do, and was more than 100 times faster than previous methods of differentiating live and dead cells.
“For some cell types, it’s extremely difficult for a person to pick up on whether a cell is alive or dead—but our computer model, by learning from GEDI, was able to differentiate them based on parts of the images we had not previously known were helpful in distinguishing live and dead cells,” says Jeremy Linsley.
Both GEDI and BO-CNN will now allow the researchers to carry out new, high-throughput studies to discover when and where brain cells die—a very important endpoint for some of the most important diseases. They can also screen drugs for their ability to delay or avoid cell death in neurodegenerative diseases. Or, in the case of cancer, they can search for drugs that hasten the death of diseased cells.
“These technologies are game changers in our ability to understand where, when, and why death occurs in cells,” says Finkbeiner. “For the first time, we can truly harness the speed and scale provided by advances in robot-assisted microscopy to more accurately detect cell death, and do so well in advance of the moment of death. We hope this can lead to more specific therapeutics for many neurodegenerative diseases that have been so far uncurable.”
Direct line: 415.734.5000
The paper “Genetically encoded cell-death indicators (GEDI) to detect an early irreversible commitment to neurodegeneration” was published by the journal Nature Communications on September 6, 2021. Other authors are Kevan Shah, Nicholas Castello, Michelle Chan, Dominic Haddad, Jay Mancini, Viral Oza, Shijie Wang, and Ashkan Javaherian of Gladstone; and David Kokel of UC San Francisco. The work at Gladstone was supported by the National Institutes of Health (U54 NS191046, R37 NS101996, RF1 AG058476, RF1 AG056151, RF1 AG058447, P01 AG054407, U01 MH115747), the National Library of Medicine (R01 LM013617), the Koret Foundation, the Taube/Koret Center for Neurodegenerative Research, and the National Center for Research Resources (RR18928).
The paper “Superhuman cell death detection with biomarker-optimized neural networks” was published by the journal Science Advances on December 8, 2021. Other authors are Josh Lamstein, Gennadi Ryan, Kevan Shah, Nicholas Castello, Viral Oza, Jaslin Kaira, Shijie Wang, Zachary Tokuno, and Ashkan Javaherian of Gladstone; and Drew Linsley and Thomas Serre of Brown University. The work at Gladstone was supported by the National Institutes of Health (U54 NS191046, R37 NS101996, RF1 AG058476, RF1 AG056151, RF1 AG058447, P01 AG054407, U01 MH115747), the National Library of Medicine (R01 LM013617), the Koret Foundation, the Taube/Koret Center for Neurodegenerative Research, the National Center for Research Resources (RR18928), the Target ALS Foundation, the Amyotrophic Lateral Sclerosis Association Neuro Collaborative, Mike Frumkin, and the Department of Defense (W81XWH-13-ALSRP-TIA).
Gladstone Institutes is an independent, nonprofit life science research organization that uses visionary science and technology to overcome disease. Established in 1979, it is located in the epicenter of biomedical and technological innovation, in the Mission Bay neighborhood of San Francisco. Gladstone has created a research model that disrupts how science is done, funds big ideas, and attracts the brightest minds.
At San Francisco’s Exploratorium, visitors sync their heartbeat with living heart cells; the first-of-its-kind exhibit was created through the museum’s long-running partnership with scientists at Gladstone Institutes.News Release Stem Cells/iPSCs Conklin Lab Yamanaka Lab Cardiovascular Disease Research (Publication)
In a new study that appears in Nature, researchers leveraged the power of a naturally occurring mutation in cancerous T cells to create a more powerful immunotherapyNews Release Research (Publication) Cancer Genomic Immunology Parker Institute for Cancer Immunotherapy Roybal Lab
New research from Gladstone may help in the development of new therapies that target the problem of cellular energy failure—a hallmark of Parkinson’s, Alzheimer’s, and aging in generalNews Release Research (Publication) Alzheimer’s Disease Parkinson’s Disease Neurological Disease Nakamura Lab CRISPR/Gene Editing